Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Case Series of Cutaneous Rothia Mucilaginosa Infection and an Important Potential Pitfall Case.

The American Journal of dermatopathology·2026

Same author

Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.

Nature communications·2026

Same author

Dermatologic Toxicities Associated With Novel Pan-RAS/RAF Inhibitors.

Journal of cutaneous pathology·2026

Same author

Expanding the Molecular Landscape of Deep Penetrating Nevus-like Melanomas Beyond CTNNB1 and APC Mutations : A Clinicopathologic and Molecular Study of 14 Cases.

The American journal of surgical pathology·2026

Same author

A Rare Case of Cutaneous Crystal-Storing Histiocytosis With Kappa Light Chain Restriction and Unusual BCL6 Expression.

Journal of cutaneous pathology·2026

Same author

Melanomas arising in blue nevi exhibit absence of TERT promoter mutations, low tumor mutational burden, and high frequency of distant metastases and disease-related mortality: a clinicopathologic and molecular study of 11 cases.

Virchows Archiv : an international journal of pathology·2026

Same journal

HER2-low as a unique subgroup in breast cancer: insights from neoadjuvant chemotherapy response and survival analysis.

Journal of clinical pathology·2026

Same journal

Polyp-forming Dieulafoy lesion of the rectum.

Journal of clinical pathology·2026

Same journal

Defining biochemical, pathological and molecular factors prognostic in terms of disease control and survival in high-grade extremity soft tissue sarcoma: a scoping review.

Journal of clinical pathology·2026

Same journal

MILGDF: a multi-task, instance-level supervised model for oral squamous cell carcinoma integrating local-global attention and dynamic decision fusion.

Journal of clinical pathology·2026

Same journal

Paediatric B-lymphoblastic leukaemia with low peripheral blasts: a potential diagnostic pitfall.

Journal of clinical pathology·2026

Same journal

MRI-targeted versus systematic needle core biopsies in prostate cancer: a patient-based analysis of potential diagnostic and biologic underestimation.

Journal of clinical pathology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 22, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Cutaneous angiosarcoma: a current update.

Elina Shustef¹, Viktoryia Kazlouskaya², Victor G Prieto¹

¹Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Journal of Clinical Pathology

|September 17, 2017

Summary

This summary is machine-generated.

Cutaneous angiosarcoma (cAS) is a rare vascular tumor. Early diagnosis is vital due to its aggressive nature and grave prognosis, prompting research into new molecular targets and therapies.

Keywords:

angiosarcoma cutaneous vascular lesions histologic mimickers histopathology immunohistochemistry molecular and therapy

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Related Experiment Videos

Last Updated: Feb 22, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Area of Science:

Oncology
Dermatology
Pathology

Background:

Cutaneous angiosarcoma (cAS) is a rare vascular neoplasm.
It presents with variable clinical features and mimics other tumors.
cAS has an aggressive behavior and poor prognosis, making early diagnosis critical.

Purpose of the Study:

To provide a comprehensive review of cutaneous angiosarcoma.
To discuss clinical, histopathological, and molecular aspects.
To cover differential diagnosis, current therapies, and clinical trials.

Main Methods:

Literature review of clinical studies.
Analysis of histopathological features.
Summary of genetic studies and molecular targets.
Review of therapeutic strategies and ongoing trials.

Main Results:

cAS diagnosis is challenging due to overlapping features with mimickers.
Recent genetic studies identified novel molecular targets for cAS treatment.
Current therapies include conventional treatments and targeted approaches.

Conclusions:

Early diagnosis of cAS is crucial for improved patient outcomes.
Understanding molecular aspects aids in developing targeted therapies.
Ongoing research and clinical trials are essential for advancing cAS treatment.